8-K: Sotera Health Raises FY26 Outlook on Strong Q2 Results

Sotera Health announced robust second-quarter 2026 financial results, exceeding expectations and prompting an upward revision of its full-year 2026 outlook.

Summary

• Sotera Health reported strong financial results for the second quarter and first half of 2026.
• Q2 2026 net revenues increased by 9.2% (8.0% constant currency) to $321.4 million compared to Q2 2025.
• Q2 2026 net income was $53.6 million, or $0.19 per diluted share, a significant increase from $7.96 million, or $0.03 per diluted share, in Q2 2025.
• Adjusted EBITDA for Q2 2026 rose by 10.0% (8.7% constant currency) to $165.7 million.
• Adjusted EPS for Q2 2026 was $0.26, a 30% increase year-over-year.
• The company is raising its full-year 2026 outlook, projecting net revenue growth of 5.25% 6.75% (constant currency) and Adjusted EBITDA growth of 5.75% 7.25% (constant currency).
• Net cash provided by operating activities was $88 million for Q2 2026.
• The Net Leverage Ratio improved to 3.0x as of June 30, 2026, meeting the company's target range.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth, improved profitability, and an increased full-year outlook, indicating robust operational performance and management confidence.

Positives

• Strong Q2 2026 net revenue growth of 9.2% (8.0% constant currency) to $321.4 million.
• Significant increase in Q2 2026 net income to $53.6 million, up from $7.96 million in Q2 2025.
• Substantial growth in Q2 2026 Adjusted EBITDA by 10.0% (8.7% constant currency) to $165.7 million.
• 30% year-over-year increase in Q2 2026 Adjusted EPS to $0.26.
• Raising the full-year 2026 outlook for both net revenue growth and Adjusted EBITDA growth.
• Sterigenics achieved 7.0% constant currency revenue growth and improved segment income margin.
• Nordion demonstrated strong performance with 16.7% constant currency revenue growth and improved segment income margin.
• Nelson Labs showed sequential segment income margin improvement.

Negatives

• Nelson Labs segment income decreased by 4.9% for the first six months of 2026 compared to the same period in 2025, despite revenue growth.
• Segment income margin for Nelson Labs in Q2 2026 was impacted by higher costs.
• The company's outlook is based on assumptions regarding supply chain continuity, particularly for ethylene oxide (EO) and Cobalt-60, and inflationary trends.

Risks

• Disruption in the availability or supply of, or increases in the price of, EO, Co-60, or other direct materials, services, and supplies.
• Geopolitical instability and sanctions impacting supply chains.
• Fluctuations in foreign currency exchange rates.
• Evolving environmental, health, and safety regulations.
• Health and safety risks associated with hazardous materials like EO and Co-60.
• Impact and outcome of current and future legal proceedings and liability claims, particularly related to EO sterilization facilities.
• Compliance with extensive regulatory requirements and potential delays in receiving required clearances or approvals.
• Business continuity hazards, including supply chain disruptions and federal government shutdowns.

Future Outlook

The company is raising its full-year 2026 outlook, projecting net revenue growth in the range of $1.236 billion to $1.254 billion (5.25% 6.75% constant currency growth) and Adjusted EBITDA growth in the range of $634 million to $643 million (5.75% 7.25% constant currency growth). Capital expenditures are expected to be between $200 million and $225 million.

Management Comments

• "We delivered another strong quarter, with high-single-digit growth, reflecting focused execution across all three of our business units."
• "These results further underscore the essential nature of Sotera Healths offerings to healthcare."
• "Since joining the Company, I have been impressed by the dedication of our teams, the trust our customers place in us and the industry-leading expertise that differentiates our business in highly regulated healthcare markets. Together, these strengths position us well to deliver consistent and reliable growth."
• "Based on our strong first-half performance and confidence in the remainder of the year, we are raising our full-year 2026 outlook. I am excited about the numerous opportunities we have for growth as we continue to deepen our customer relationships, invest in our people, facilities and capabilities, and execute on our long-term strategy."

Industry Context

StockSavvy.ai notes that Sotera Health operates in the critical healthcare services sector, providing essential sterilization, lab testing, and advisory services. The strong performance, particularly in sterilization services (Sterigenics) and medical isotopes (Nordion), highlights the consistent demand for these mission-critical offerings, even amidst broader economic uncertainties. The company's ability to grow revenue and profitability underscores the resilience and essential nature of its services within the healthcare ecosystem.

Comparison to Industry Standards

• The company's Adjusted EBITDA margin of 51.6% in Q2 2026 is notably high, suggesting strong operational efficiency and pricing power within its specialized market segments.
• While specific direct competitors' Q2 2026 results are not provided in this filing, Sotera Health's consistent high-single-digit revenue growth (constant currency) generally outperforms broader healthcare services industry averages, which often experience mid-single-digit growth.
• The achievement of the Net Leverage Ratio target range (2.0x-3.0x) at 3.0x is a positive indicator of financial health, often a benchmark for stable companies in capital-intensive sectors.

Legal Proceedings

• Ongoing litigation related to the use, emissions, and releases of EO from current and former EO sterilization facilities.

Stakeholder Impact

• Shareholders: Positive impact due to improved financial performance, raised outlook, and achievement of leverage targets.
• Employees: Continued investment in people and strong performance may lead to job security and potential growth opportunities.
• Customers: Continued provision of essential sterilization, lab testing, and advisory services, with a focus on deepening relationships.
• Suppliers: Continued demand for materials and services, with potential price pressures noted in the outlook assumptions.

Next Steps

• Continue to deepen customer relationships.
• Invest in people, facilities, and capabilities.
• Execute on the long-term strategy.
• Participate in the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026.

Key Dates

Recommendation

While the results are strong and the outlook has been raised, the company operates in a highly regulated environment with ongoing legal proceedings (EO litigation) that present significant risks. The current leverage is at the upper end of the target range. Therefore, a 'hold' recommendation is prudent, allowing investors to assess the sustainability of growth against these risks.

Keywords

sterilization solutions, healthcare industry, Sterigenics, Nordion, Nelson Labs, financial results, revenue growth, Adjusted EBITDA